Aeterna Zentaris first quarter revenues increase to $7.

Aeterna Zentaris first quarter revenues increase to $7 dapoxetine 30 mg .4 million Aeterna Zentaris Inc. One fourth 2011 Highlights Agreement signed with Yakult Honsha Co First. Ltd. for the development, commercialization and manufacture of perifosine, in Japan.5 million) upon achieving certain pre-founded milestones, including medical and regulatory events in Japan, along with double-digit royalties on future net sales of perifosine in Japan. The Company has decided to supply perifosine, on a cost-plus-basis, to Yakult.Receipt of net sales royalty milestone payment of $2.5 million from Cowen Healthcare Royalty Partners, L.P.$1.5 million grant, payable over a three-year period as partial reimbursement of qualifying expenditures, awarded to the Company by the German Ministry of Education and Study to develop, to the medical stage up, cytotoxic conjugates of the proprietary cytotoxic compound disorazol Z and peptides targeting G-protein coupled receptors, like the luteinizing hormone-releasing hormone receptors.At-the-Market sales contract signed to market common shares through ATM issuances on the NASDAQ for aggregate gross proceeds not to exceed $19.